Video

Dr. Douglas Paauw gives updates on antihypertensives, statins, SGLT2 inhibitors


 

REPORTING FROM INTERNAL MEDICINE 2019

Douglas S. Paauw, MD, discussed why it’s been a bad year for antihypertensives, and provided updates on the side effects of statins and sodium-glucose cotransporter 2 inhibitors, in a video interview at the annual meeting of the American College of Physicians.

Dr. Paauw, professor of medicine at the University of Washington, Seattle, began by discussing some of the issues that occurred with antihypertensive drugs in the past year. These included the link between hydrochlorothiazide use and the increased risk of nonmelanoma skin cancers, the recalls of many drug lots of angiotensin II receptor blockers, and a study that found an increased risk of lung cancer in people who were taking ACE inhibitors.

He then described the findings of studies that examined the links between statins and muscle pain and other new research on these drugs.

He also warned physicians to be particularity cautious about prescribing sodium-glucose cotransporter 2 inhibitors to certain kinds of patients.

Dr. Paauw concluded by explaining why clarithromycin is his most hated drug.

Dr. Paauw is also the Rathmann Family Foundation Endowed Chair for Patient-Centered Clinical Education and the medicine clerkship director at the University of Washington.

Recommended Reading

CV disease and mortality risk higher with younger age of type 2 diabetes diagnosis
Clinician Reviews
Alirocumab reduces both type 1 and 2 MIs
Clinician Reviews
Dapagliflozin’s cardiovascular benefits bloom in T2D with prior MI
Clinician Reviews
New data further suggest that stress does a number on the CV system
Clinician Reviews
Coughing Won’t Pay the Bills
Clinician Reviews
Low LDL cholesterol may increase women’s risk of hemorrhagic stroke
Clinician Reviews
PIONEER-HF Extension: Don’t stall starting sacubitril/valsartan
Clinician Reviews
Canagliflozin lowers kidney failure risk in T2D: CREDENCE
Clinician Reviews
Poor response to statins hikes risk of cardiovascular events
Clinician Reviews
Dr. Joseph Vassalotti: Cancer risk minimal with ARBs
Clinician Reviews